A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy

NCT02644486 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped difficulty in enrollment

Conditions

Obesity and Glomerulopathy

Interventions

DRUG: High dosage Sevelamer Carbonate + Irbesartan
DRUG: Low dosage Sevelamer Carbonate + Irbesartan
DRUG: Irbesartan

Sponsor

Zhi-Hong Liu, M.D.